Creo Medical (1RC) Ratios
2 Followers
Creo Medical Ratios
DE:1RC's free cash flow for Q4 2025 was £-34.20M. For the 2025 fiscal year, DE:1RC's free cash flow was increased by £0.00 and operating cash flow was £-34.20M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.22 | 2.75 | 3.83 | 1.93 | 3.10 |
| Quick Ratio | 2.88 | 2.62 | 3.01 | 1.39 | 2.67 |
| Cash Ratio | 1.70 | 0.42 | 0.30 | 0.75 | 2.21 |
| Solvency Ratio | 0.69 | -1.16 | -1.09 | -0.92 | -0.81 |
| Operating Cash Flow Ratio | -2.62 | -1.08 | -2.18 | -1.43 | -1.32 |
| Short-Term Operating Cash Flow Coverage | -8.30 | -10.09 | -8.64 | -5.00 | -5.51 |
| Net Current Asset Value | £ 14.40M | £ 33.80M | £ 21.10M | £ 7.75M | £ 33.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.07 | 0.11 | 0.16 | 0.10 |
| Debt-to-Equity Ratio | 0.08 | 0.10 | 0.14 | 0.24 | 0.14 |
| Debt-to-Capital Ratio | 0.08 | 0.09 | 0.12 | 0.19 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.04 | 0.07 | 0.09 | 0.05 |
| Financial Leverage Ratio | 1.18 | 1.53 | 1.28 | 1.52 | 1.37 |
| Debt Service Coverage Ratio | -7.58 | -9.58 | -6.17 | -4.49 | -4.30 |
| Interest Coverage Ratio | -69.00 | -72.00 | -62.00 | -124.22 | -82.53 |
| Debt to Market Cap | 0.10 | 0.06 | 0.05 | 0.21 | 0.03 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.03 | 0.06 | 0.06 |
| Net Debt to EBITDA | 0.42 | 0.16 | -0.26 | 0.05 | 1.20 |
| Profitability Margins | |||||
| Gross Profit Margin | 23.33% | 47.50% | 49.68% | 36.84% | 35.86% |
| EBIT Margin | -345.00% | -715.00% | -78.25% | -112.63% | -119.14% |
| EBITDA Margin | -328.33% | -652.50% | -67.21% | -101.65% | -109.46% |
| Operating Profit Margin | -345.00% | -720.00% | -80.52% | -113.39% | -119.07% |
| Pretax Profit Margin | -291.67% | -725.00% | -79.55% | -114.02% | -120.58% |
| Net Profit Margin | 88.33% | -717.50% | -70.45% | -99.14% | -97.75% |
| Continuous Operations Profit Margin | -291.67% | -695.00% | -76.95% | -99.01% | -97.75% |
| Net Income Per EBT | -30.29% | 98.97% | 88.57% | 86.95% | 81.07% |
| EBT Per EBIT | 84.54% | 100.69% | 98.79% | 100.55% | 101.27% |
| Return on Assets (ROA) | 8.97% | -44.15% | -28.33% | -35.75% | -24.45% |
| Return on Equity (ROE) | 10.60% | -67.69% | -36.29% | -54.52% | -33.55% |
| Return on Capital Employed (ROCE) | -39.96% | -64.72% | -37.18% | -53.25% | -37.04% |
| Return on Invested Capital (ROIC) | -38.26% | -58.87% | -31.47% | -42.22% | -28.16% |
| Return on Tangible Assets | 9.17% | -44.50% | -43.06% | -95.75% | -44.89% |
| Earnings Yield | 12.98% | -40.69% | -15.07% | -56.78% | -9.69% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.87 | 3.08 | 3.90 | 5.43 | 5.64 |
| Payables Turnover | 0.94 | 2.33 | 5.74 | 3.99 | 4.56 |
| Inventory Turnover | 1.84 | 0.78 | 1.91 | 1.84 | 1.90 |
| Fixed Asset Turnover | 1.76 | 0.68 | 3.38 | 2.67 | 2.92 |
| Asset Turnover | 0.10 | 0.06 | 0.40 | 0.36 | 0.25 |
| Working Capital Turnover Ratio | 0.23 | 0.13 | 1.39 | 0.94 | 0.61 |
| Cash Conversion Cycle | 229.32 | 431.48 | 220.78 | 174.06 | 177.02 |
| Days of Sales Outstanding | 419.75 | 118.63 | 93.62 | 67.17 | 64.70 |
| Days of Inventory Outstanding | 198.37 | 469.29 | 190.74 | 198.35 | 192.34 |
| Days of Payables Outstanding | 388.80 | 156.43 | 63.58 | 91.46 | 80.02 |
| Operating Cycle | 618.12 | 587.91 | 284.36 | 265.52 | 257.04 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.05 | -0.06 | -0.07 | -0.13 | -0.15 |
| Free Cash Flow Per Share | -0.05 | -0.06 | -0.07 | -0.15 | -0.19 |
| Dividend Paid and CapEx Coverage Ratio | -21.22 | -55.50 | -18.00 | -7.63 | -4.24 |
| Capital Expenditure Coverage Ratio | -21.22 | -55.50 | -18.00 | -7.63 | -4.24 |
| Operating Cash Flow Coverage Ratio | -4.66 | -5.05 | -2.60 | -2.14 | -2.46 |
| Operating Cash Flow to Sales Ratio | -3.18 | -5.55 | -0.70 | -0.92 | -1.03 |
| Free Cash Flow Yield | -48.98% | -32.05% | -15.84% | -59.57% | -12.65% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 7.73 | -2.46 | -6.64 | -1.76 | -10.32 |
| Price-to-Sales (P/S) Ratio | 6.81 | 17.63 | 4.67 | 1.75 | 10.09 |
| Price-to-Book (P/B) Ratio | 0.82 | 1.66 | 2.41 | 0.96 | 3.46 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.04 | -3.12 | -6.32 | -1.68 | -7.91 |
| Price-to-Operating Cash Flow Ratio | -2.14 | -3.18 | -6.67 | -1.90 | -9.77 |
| Price-to-Earnings Growth (PEG) Ratio | -0.07 | -0.17 | 0.13 | 0.00 | -1.34 |
| Enterprise Value Multiple | -1.65 | -2.54 | -7.21 | -1.67 | -8.02 |
| Enterprise Value | 32.53M | 66.23M | 149.28M | 46.05M | 220.89M |
| EV to EBITDA | -1.65 | -2.54 | -7.21 | -1.67 | -8.02 |
| EV to Sales | 5.42 | 16.56 | 4.85 | 1.69 | 8.78 |
| EV to Free Cash Flow | -1.63 | -2.93 | -6.55 | -1.63 | -6.88 |
| EV to Operating Cash Flow | -1.70 | -2.98 | -6.91 | -1.84 | -8.50 |
| Tangible Book Value Per Share | 0.12 | 0.12 | 0.11 | 0.01 | 0.16 |
| Shareholders’ Equity Per Share | 0.12 | 0.12 | 0.19 | 0.26 | 0.43 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.04 | 0.11 | 0.13 | 0.19 |
| Revenue Per Share | 0.01 | 0.01 | 0.10 | 0.14 | 0.15 |
| Net Income Per Share | 0.01 | -0.08 | -0.07 | -0.14 | -0.14 |
| Tax Burden | -0.30 | 0.99 | 0.89 | 0.87 | 0.81 |
| Interest Burden | 0.85 | 1.01 | 1.02 | 1.01 | 1.01 |
| Research & Development to Revenue | 1.25 | 2.77 | 0.38 | 0.50 | 0.51 |
| SG&A to Revenue | 3.85 | 7.58 | 1.31 | 1.62 | 1.65 |
| Stock-Based Compensation to Revenue | 0.23 | 0.38 | 0.04 | 0.05 | 0.10 |
| Income Quality | 1.09 | 0.80 | 1.00 | 0.93 | 1.06 |
Currency in GBP
